 An early phase II, single arm, two stage study, to investigate the level of activity, duration of response and tolerability of brentuximab vedotin SGN-35, as a single agent, utilising a response adapted approach, in older, frailer or co-morbid patients with previously untreated Hodgkin lymphoma. 